Are you optimizing
clinical intelligence?

The right data and strategic insights are often elusive. That is why MDCPartners takes deeper dives for our clients in the pharmaceutical and medical industries. By merging our business expertise with unique IT platforms and portals we can fully support your intelligence and business needs for clinical trial optimization, medical expert identification, and regulatory compliance.

Strategic data advances clinical development

MDCPartners is dedicated to providing tools and services to help pharmaceutical companies make better decisions. Our flagship product, ta-Scan, is a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data, and expert profiles. Whether you need to optimize study placement, select research partners, or manage your portfolios, our products and portals will help you bridge the information gaps in today’s competitive clinical research environment.

Learn more about ta-Scan 5

Are your medical devices meeting standards?

To support manufacturers of medical devices and in vitro diagnostics (IVDs), MDCPartners has developed normScan, a web-based standards tracking tool tailored to your product range. It can also help you obtain regulatory approval for marketing products throughout Europe, and can assist you with a broad spectrum of regulatory issues related to maintaining compliance.

Learn more about normScan

Bring your own data, use our know-how

MDCPartners doesn’t just offer tools for visualizing public data. We also provide tools for depicting external client data merged with information from our public data cloud. So if you have specific needs that surpass the scope of ta-Scan, you can still rely on us for tailor-made real world data solutions.

Learn more about our data solutions

Latest News & Events

ta-Scan and MDCPartners at Immuno-Oncology Summit 2017 Boston

Connect with MDCPartners at the Immuno-Oncology Summit 2017

Connect with MDCPartners at Immuno-Oncology Summit 2017 from August 28 to September 1, 2017 in Boston, MA. Visit MDCPartners at booth #32 to discover next generation targeted immunotherapies and find new ways to navigate clinical data and overlap internal data with MDCPartners’ public data cloud.

Join us in Boston

Would you like to know how our clinical business intelligence software ta-Scan or our other data solutions can help with your company’s data challenges? Then feel free to pop by booth #32 or make an appointment with MDCPartners’ Director of Business Development, North America Matt Tumasz and/or Strategic Analyst, Oncology, Dr. Jonathan Crowther. They will gladly show you our state of the art tools.

Register Today

Secure your place now if you want to connect with the ta-Scan team in Boston. MDCPartners has arranged for an exclusive discount on CHI’s Immuno-Oncology Summit. Use promo code MDC when registering to receive your $200 registration discount. This discount applies to conference programs only and cannot be used on short courses, combined with other offers, or transferred.

How to register:
Online: https://chidb.com/reg/imx/reg.asp
By Phone: +1 781-972-5472

Immuno-Oncology Summit 2017 Program

Now in its fifth year, the Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

This year’s IO Summit has been designed to give attendees a complete picture of the field and its advances with 12 conference tracks, 1 in-depth training seminar, and 4 instructional short courses. Topics include immunotherapy discovery, development, biomarkers, and translational oncology as well as emerging topic areas such as cancer vaccines, oncolytic viruses, and advances in synthetic biology techniques. Overall, this event provides a focused look at how researchers are applying new science and technology in the development of effective and safe immunotherapies.

Download the digital brochure for full details.

We look forward to seeing you in Boston!

Share on:
Tweet about this on TwitterShare on LinkedIn
DIA 2017 ta-Scan mobile app David Cocker

Meet David Cocker at DIA 2017 and discover the new ta-Scan mobile app!

MDCPartners’ CSO David Cocker will be attending the DIA 2017 meeting in Chicago on June 18-22 to showcase ta-Scan‘s new mobile app.

About DIA 2017

The Drug Information Association, a non-profit association, is the only global organization dedicated to bringing health care product development professionals together in a trusted, global, neutral environment to share insights and drive action in health care product development and life cycle management.

ta-Scan Mobile App

ta-Scan now has its own mobile app! Have a look at the video below: it’s a little demo on how it works. This tool enables MSLs to search for high ranking investigators on the go. Clinical business intelligence is now truly at your fingertips.

Meet us in Chicago

Book an appointment now to connect with David Cocker in Chicago.

We look forward to seeing you in Chicago!

Share on:
Tweet about this on TwitterShare on LinkedIn
ASCO 2017 ta-scan analysis

Curious about what to expect at ASCO 2017? ta-Scan has you covered!

As ASCO 2017 kicks off this Friday, finding the information relevant to you can be a hassle. Using ta-Scan, you can quickly uncover key information about sponsors, clinical trials, drugs and investigators contributing to ASCO this year. To help you out, we highlight a few interesting points.

asco 2017 abstracts

Abstracts

Over the past 3 years, there have been some notable changes in therapeutic areas discussed at the American Society of Clinical Oncology’s annual meeting. It comes as no surprise that the Immune Oncology trend is growing year on year, much like Lung Cancer. On the other hand, interest in Breast Cancer is steadily declining, which could be due to the disappointing results of Immune Oncology within Breast Cancer. Another interesting fact is the gain in Gastrointestinal Cancer abstracts at this year’s conference, after a relatively quiet 2016.

asco 2017 abstracts ta distribution

Sponsor & trial activity

Of the 1,203 clinical trials that are cited at ASCO 2017, 6 key commercial sponsors have seen considerable fluctuations in trial activity when compared to ASCO 2016. Significant gains can be seen in the trial activity of BMS, Pfizer, and Roche, whereas Novartis, Sanofi, and Johnson & Johnson have seen a decrease in trial numbers.

asco 2017 abstracts ta distribution

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts pd-pd-l

Investigator & sponsor collaborations

Looking at the percentage of top Oncology experts used by the leading commercial sponsors of trials talked about at ASCO 2017, it’s clear that Roche and Merck have an evenly distributed usage of investigators in both the USA as well as Europe, whereas others seem to lean toward USA investigator preference.

asco 2017 abstracts top oncology investigators

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts new drugs

Learn more about ta-Scan

Interested in ta-Scan‘s analytical services? Request your free webinar here or contact us.

Share on:
Tweet about this on TwitterShare on LinkedIn

Downloads

  • ta-Scan's Trial Feasibility Wizard

    More information about ta-Scan's Trial Feasibility Wizard in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Expert Profiling & Exploring Disease Landscapes

    Learn how to use ta-Scan for expert profiling and exploring disease landscapes.

    US Letter Format | A4 Format
  • ta-Scan for Competitive Intelligence & Medical Affairs

    Learn how to use ta-Scan for competitive intelligence and medical affairs in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Clinical Trial Planning & Optimization

    Learn how to use ta-Scan for clinical trial planning and optimization in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan's Research Landscape Comparison Wizard

    More information about ta-Scan's RLC Wizard in this fact sheet.

    US Letter Format | A4 Format

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page